Acute Kidney Injury (AKI) Clinical Trial
Official title:
A Safety Evaluation of Prismocitrate 18 in Patients Receiving Continuous Renal Replacement Therapy (CRRT)
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the PrisMax System allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription. The study period of the patient's CRRT will be up to 10 days.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03941483 -
Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
|
Phase 2 | |
Completed |
NCT02733328 -
Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
|
||
Completed |
NCT04829916 -
A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery
|
Phase 1 | |
Completed |
NCT05068167 -
Acute Kidney Injury as a Risk Factor for Myocardial Injury After Non Cardiac Surgery
|
||
Completed |
NCT04165369 -
Observational Study to Evaluate the Epidemiology of Surgical-induced Acute Kidney Injury
|
||
Terminated |
NCT02620761 -
Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants
|
Phase 2/Phase 3 | |
Recruiting |
NCT05264285 -
Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|